A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Exclusion Criteria

• •1. Received any investigational drug within 28 days prior to study enrollment
• •2. Received blood transfusion or any therapies with erythropoietin (EPO), granulocyte-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study enrollment
• •3. Received previous immunotherapy
• •4. Received or plan to receive a live vaccine within 28 days of study enrollment
• •5. Major surgery within 28 days of study enrollment
• •6. Received systemic steroid therapy with 28 days of study enrollment
• •7. Received or plan to receive the hematopoietic cell transplant
• •8. History of gastrointestinal perforation and/or fistula within 6 months prior to study enrollment
• •9. Known allergic reactions against monoclonal antibody or rituximab.
• •10. Received rituximab or other anti-CD20 monoclonal antibody
• •11. Blood concentration of rituximab \> 10 ug/mL during screen visit
• •12. Human immunodeficiency virus (HIV) positive
• •13. Hepatitis C virus (HCV) antigen and antibody positive
• •14. Hepatitis B virus surface antigen (HBsAg) positive
• •15. Body Mass Index (MBI) ≥ 28 kg/m2